Cardizem La is a drug owned by Bausch Health Us Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 25, 2021. Details of Cardizem La's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6923984 | Cushioning wax beads for making solid shaped articles |
Feb, 2021
(3 years ago) |
Expired
|
| US7108866 | Chronotherapeutic diltiazem formulations and the administration thereof |
Dec, 2019
(4 years ago) |
Expired
|
| US5529791 | Extended release form of diltiazem |
Jun, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Cardizem La's patents.
Latest Legal Activities on Cardizem La's Patents
Given below is the list of recent legal activities going on the following patents of Cardizem La.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed Critical | 02 Aug, 2005 | US6923984 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 02 Aug, 2005 | US6923984 (Litigated) |
| Issue Notification Mailed Critical | 13 Jul, 2005 | US6923984 (Litigated) |
| Receipt into Pubs | 09 Jun, 2005 | US6923984 (Litigated) |
| Dispatch to FDC | 08 Jun, 2005 | US6923984 (Litigated) |
| Application Is Considered Ready for Issue Critical | 08 Jun, 2005 | US6923984 (Litigated) |
| Receipt into Pubs | 07 Jun, 2005 | US6923984 (Litigated) |
| Workflow - File Sent to Contractor | 11 Apr, 2005 | US6923984 (Litigated) |
| Issue Fee Payment Received Critical | 23 Mar, 2005 | US6923984 (Litigated) |
| Issue Fee Payment Verified Critical | 23 Mar, 2005 | US6923984 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but Cardizem La is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Cardizem La's family patents as well as insights into ongoing legal events on those patents.
Cardizem La's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Cardizem La's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 25, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Cardizem La Generic API suppliers:
Diltiazem Hydrochloride is the generic name for the brand Cardizem La. 37 different companies have already filed for the generic of Cardizem La, with Actavis Labs Fl Inc having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Cardizem La's generic
How can I launch a generic of Cardizem La before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Cardizem La's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Cardizem La's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Cardizem La -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 120 mg, 180 mg, 240 mg, 300 mg and 360 mg | 30 Aug, 2005 | 1 | 15 Mar, 2010 | 25 Jun, 2013 | Deferred |
| 420 mg | 25 Apr, 2005 | 1 | 15 Mar, 2010 | 25 Jun, 2013 | Deferred |
Alternative Brands for Cardizem La
Cardizem La which is used for managing high blood pressure and chest pain., has several other brand drugs in the same treatment category and using the same active ingredient (Diltiazem Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Bausch |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Diltiazem Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Bausch |
| |
| Biovail |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Diltiazem Hydrochloride, Cardizem La's active ingredient. Check the complete list of approved generic manufacturers for Cardizem La
About Cardizem La
Cardizem La is a drug owned by Bausch Health Us Llc. It is used for managing high blood pressure and chest pain. Cardizem La uses Diltiazem Hydrochloride as an active ingredient. Cardizem La was launched by Bausch in 2003.
Approval Date:
Cardizem La was approved by FDA for market use on 06 February, 2003.
Active Ingredient:
Cardizem La uses Diltiazem Hydrochloride as the active ingredient. Check out other Drugs and Companies using Diltiazem Hydrochloride ingredient
Treatment:
Cardizem La is used for managing high blood pressure and chest pain.
Dosage:
Cardizem La is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 120MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 360MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 180MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 420MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |
| 240MG | TABLET, EXTENDED RELEASE | Prescription | ORAL |